Botulinum toxin is being studied more seriously as an early scar-modulation tool.
A 2026 systematic review and meta-analysis pooled 19 studies involving 686 patients and found better scar scores, narrower scars and higher satisfaction with botulinum toxin type A, while also calling for larger, more uniform trials. That makes it an evidence-building option for selected fresh scars rather than a blanket recommendation for every incision.
Reviewed for the Dagan Edit
Share quietly
Renaissance-style scar-revision study showing skin tension lines and early scar-planning concepts; not an actual patient result
The report, in context
What this development means—and what it does not.
A 2026 systematic review and meta-analysis pooled 19 studies involving 686 patients and found better scar scores, narrower scars and higher satisfaction with botulinum toxin type A, while also calling for larger, more uniform trials. That makes it an evidence-building option for selected fresh scars rather than a blanket recommendation for every incision.
Inclusion is not an endorsement; treatment suitability, product safety and postoperative care require individualized guidance from a qualified clinician.
